Primary lymphedema is due to developmental and/or functional defects in the lymphatic system. It may affect any part of the body, with predominance for the lower extremities. Twenty-seven genes have already been linked to primary lymphedema, either isolated, or as part of a syndrome. The proteins that they encode are involved in VEGFR3 receptor signaling. They account for about one third of all primary lymphedema cases, underscoring the existence of additional genetic factors. We used whole-exome sequencing to investigate the underlying cause in a non-consanguineous family with two children affected by lymphedema, lymphangiectasia and distinct facial features. We discovered bi-allelic missense mutations in ADAMTS3. Both were predicted to be highly damaging. These amino acid substitutions affect well-conserved residues in the prodomain and in the peptidase domain of ADAMTS3. In vitro, the mutant proteins were abnormally processed and sequestered within cells, which abolished proteolytic activation of pro-VEGFC. VEGFC processing is also affected by CCBE1 mutations that cause the Hennekam lymphangiectasia-lymphedema syndrome syndrome type1. Our data identifies ADAMTS3 as a novel gene that can be mutated in individuals affected by the Hennekam syndrome. These patients have distinctive facial features similar to those with mutations in CCBE1. Our results corroborate the recent in vitro and murine data that suggest a close functional interaction between ADAMTS3 and CCBE1 in triggering VEGFR3 signaling, a cornerstone for the differentiation and function of lymphatic endothelial cells.
Introduction
The lymphatic system is essential for tissue and body fluid homeostasis. During development, lymphatic endothelial cells differentiate from veins upon combined action of the PROX1 and SOX18 transcription factors. Several other proteins are KRAS, PTPN11, PTPN14, RAF1, RASA1, SOS1, SOX18 and VEGFC (reviewed by Brouillard et al (1) ), as well as CELSR1 (2), EPHB4 (3), FAT4 (4), PIEZO1 (5,6), RELN (7), RIT1 (8), (9) , TSC1 and TSC2 (10). These genes account for about one third of patients with primary lymphedema.
The central axis controlling lymphangiogenesis involves the VEGFR3 receptor (encoded by FLT4) and its ligand, VEGFC. More than 100 patients (families) have been reported with dominant, recessive, or de novo inactivating mutations in VEGFR3 (1) , and two with a loss-of-function mutation in VEGFC (11, 12) . One recessive homozygous mutation in PTPN14, a VEGFR3-specific phosphatase, was discovered in a large consanguineous family (13) . Moreover, the extracellular protein CCBE1, which is involved in the activation of VEGFC (14) , is mutated in individuals with the Hennekam syndrome (OMIM 235510) (15, 16) . Patients with this recessive syndrome have generalized lymphatic anomalies, a dysmorphic face and cognitive impairment. Mice deficient in Ccbe1 die due to lymphatic abnormalities (17) . Recent biochemical data indicate that ADAMTS3 is a direct partner of CCBE1 required for VEGFC activation (14) .
Here, we report the identification of a novel gene mutated in primary lymphedema. We discovered compound heterozygous mutations in ADAMTS3 in two siblings with a phenotype reminiscent of the Hennekam lymphangiectasia-lymphedema syndrome. The unaffected parents were each a carrier for one of the mutations. We show that each of the ADAMTS3 mutations results in sequestration of the enzyme within the cell, and thus, in the compound heterozygous state of the affected siblings, a complete loss of ADAMTS3 function in regard to VEGFC activation. This underscores the crucial role of ADAMTS3 in the regulation of VEGFR3 signaling pathway.
Results

A family with mutations in ADAMTS3
The parents in family LE-69 are of Western European origin and non-consanguineous, with no familial history of primary lymphedema or other lymphatic problems. They were clinically examined and appeared healthy. The mother gave birth to two children, a girl (LE-69-10) and a boy (LE-69-11), who both presented with polyhydramnios and congenital lymphedema of the lower extremities (as well as hydroceles for the boy) (Fig. 1A) .
The girl had a prolonged intensive care unit stay, primarily related to her lymphedema and feeding problems. She also has protein-losing enteropathy, which at one time required elemental formula feeding via a gastrostomy tube. Her lymphedema is rather widespread, but worse in the left lower extremity. Increasing severity occurs in a dependent course, but is present in her face, abdomen, genitalia and legs. The facial lymphedema is minimal. Her physical features of note include: flat facies, hypertelorism (intercanthal distance 4.25 cm), synophrys, pseudo-strabismus, upward-slanting palpebral fissures, and anteverted peaked nostrils. She has an unusual stellate shaped umbilicus. She has a normal chest and cardiovascular exam. She has no hepatosplenomegaly. She has growth hormone deficiency, which is responding well to therapy, and complex migraines. Otherwise, she is a healthy adolescent.
Her brother has had a more benign course. He had less edema at birth. He had a spontaneous pneumothorax and required a chest tube. He also had protein-losing enteropathy, but to a lesser degree than his sister, and never required gastrostomy feeding. He has no hepatic involvement and no evidence of growth hormone deficiency. He has facial features similar to those of his sister, including hypertelorism (intercanthal distance 4 cm) and strabismus. He has minimal facial lymphedema. Lymphedema in the extremities is more pronounced on the left side. Secondary changes of his feet are milder than those of his sister.
A rather unusual finding noticed in the girl, and to a lesser degree in her brother, is the nearly complete resolution of the lymphedema during febrile illness. She may even do without her compression garments during these episodes. This is not due to dehydration, nor to use of non-steroidal anti-inflammatory agents. Incidentally, the girl has a chromosome 14p deletion inherited from the unaffected father; no karyotype was performed for the boy.
In order to identify the genetic cause of primary lymphedema in this family, we explored the whole-exome sequencing data from the index patient (LE-69-10, Fig. 1A ) using Highlander (Helaers et al, under revision). We unraveled only one heterozygous polymorphism in CCBE1 (rs200772179, present 61 times in gnomAD (http://gnomad.broadinstitute.org)) and no change in FAT4. However, we discovered two concomitant nucleotide changes in ADAMTS3. The corresponding amino acid substitutions were predicted to be damaging or deleterious by Polyphen 2, Mutation Taster, SIFT, LRT, and with medium or high impact by Mutation Assessor. Variant c.503 T > C (nucleotide 503 from the ATG of ADAMTS3) results from an A-to-G substitution at position 73, 414, 196 on chromosome 4 (based on reference genome assembly hg19), which predicts a leucine 168 to a proline substitution (p.Leu168Pro). This change was found in the affected siblings (LE-69-10 and -11) and the unaffected father (Fig. 1A) . The second variant found in the girl (LE-69-10), was an A-to-G change at position 73, 188, 804, corresponding to a c.872 T > C (p.Ile291Thr) substitution. It was also detected in the brother and the unaffected mother. Neither variant was present in the 60, 706 WES of ExAC, the 250 trios of GoNL (Genome of the Netherlands), nor our internal cohort of 645 sequenced samples. The c.503 T > C (p.Leu168Pro) is present once within the 245, 264 alleles in gnomAD, whereas the c.872 T > C (p.Ile291Thr) is not. Thus, the changes are extremely rare, which corroborates the note that the two children are compound heterozygotes for two recessive mutations in ADAMTS3. No other homozygous or compound heterozygous mutation in ADAMTS3 was found within 78 additional primary lymphedema index patients sequenced.
ADAMTS3-L168 and I291 are conserved residues
The c.503 T > C; p.Leu168Pro (L168P) and c.872 T > C; p.Ile291Thr (I291T) substitutions were predicted to be damaging by several software programs. However, they were not localized in domains known to be crucial for ADAMTS3 activity, such as the furin cleavage site or the amino acids of the peptidase domain involved in zinc binding and catalytic activity (Fig. 1B) . Therefore, we aligned the amino acid sequences of ADAMTS3 from different species (from human to fish and reptile), focusing on the regions encompassing the mutations (Fig. 2A) . The prodomain (ending at the furin cleavage site, Fig. 1B ) is only moderately conserved. However, the L168P mutation is in the center of a fully conserved 9-amino acid stretch (N-C-D-G-L-A-G-M-I), suggesting an important role in enzymatic function. The second mutation is located in the first half of the metalloproteinase domain, between the furin and the zinc-binding catalytic site (Fig. 1B) . This domain is well conserved among different species, and remarkably, the I291T mutation is located within one of the most conserved stretches of the sequence (Fig. 2A, right panel) .
We also verified the nature of the amino acids at these positions in the 18 other human ADAMTS proteins (Fig. 2B) . The L168 residue is embedded in a specific signature (S-X-C-X-G-L-X-G) in the prodomain of all ADAMTSs (except ADAMTS13, which contains a truncated prodomain). Proline is never present at this position. Alignment at the level of the second mutation also revealed a conserved sequence and showed that either I or L are the preferred amino acids (with M and A being present in ADAMTS17 and ADAMTS4, respectively). T is never observed at this position. Alignments were finally performed with sequences of human ADAM family members (a family distinct but related to ADAMTS) (Fig. 2C) . This revealed the same S-X-C-X-G-L-X-G signature at the level of the L168P mutation and showed that an aliphatic amino acid (I, V, L) is found at the I291T position, as in the ADAMTSs. Altogether these data strongly favor a damaging effect of the two mutations identified in our patients.
Mutant ADAMTS3 proteins are abnormally cleaved and not secreted in the conditioned medium
The extent of the damaging effect of the identified mutations could not be predicted. Therefore, we developed a model allowing regulation of the level of production of the recombinant proteins in order to create conditions suitable for the identification of small activity differences. Cell layers and culture media obtained from control and induced cells were analyzed by Western blotting. With an antibody targeting the C-terminal end of ADAMTS3, a 166 kDa product, corresponding to the propeptide, was identified in the cell layer of the wild-type (WT) and the two mutants (Fig. 3A) . No immunoreactive material was detected in the conditioned medium.
A second antibody, raised against an ADAMTS3 fragment encompassing the prodomain, confirmed the presence of a 166 kDa product in the cell layer of all the clones (Fig. 3B , upper band). In cells expressing WT-ADAMTS3, additional bands were observed in the cell layer (at 139 and 36 kDa) and in the conditioned culture medium (36 and 25 kDa) (see Supplementary Material, Fig. S1 for details of the fragments), demonstrating secretion and illustrating the complex process of maturation and cleavage of WT-ADAMTS3. The active form of ADAMTS3, which has lost its prodomain and should migrate at 100-110 kDa, cannot be detected by this antibody. The distribution pattern for the L168P mutant indicated that the mutant enzyme accumulated in the cell layer as the 166 kDa full-length polypeptide, while it was undetectable in the culture medium (Fig. 3B ). For the I291T mutant, the 166 kDa pro-ADAMTS3 was also observed in the cell layer, together with other products (of 125, 97 and 47 kDa) absent from cells expressing the WT enzyme. No signal was detected in the culture medium.
The maturation process of ADAMTS3 involves the cleavage of the prodomain by proprotein convertases, such as furin, as well as the removal of most of the procollagen N-propeptidase C-terminal domain by cleavage at a site that remains to be defined Fig. S1 ) (18) . Since the commercially available ADAMTS3 antibodies are specific for the N-or the C-terminal, they did not allow visualization of the active central domain. To overcome this, we inserted an HA-epitope in the spacer region of ADAMTS3 (Fig. 1B, Supplementary Material, Fig. S1 ), according to a strategy successfully used previously for ADAMTS2 (18) . The use of an anti-HA antibody confirmed the presence of the 166 and 139 kDa products, as well as products migrating at 100-110 kDa in cells expressing WT-ADAMTS3 (Fig. 3C ). In the conditioned medium, a 106 kDa band was identified, corresponding to the released active form of ADAMTS3. Moreover, very high molecular weight products were observed, consisting of cleaved ADAMTS3 in complex with alpha2-macroglobulin (Fig. 3C ). The latter is an almost universal inhibitor of endoproteinases, including matrix metalloproteinases and ADAMs. It presents a cleavable 'bait' that, once proteolytically cleaved, causes conformational changes that entrap the proteinase. It becomes then covalently anchored by transacylation. Formation of a covalent complex with alpha2-macroglobulin is therefore a sign of proteolytic activity of ADAMTS3 (19) . For both mutants, the patterns of proteolytic maturation of ADAMTS3 were clearly altered, and no ADAMTS3 was detected in the conditioned medium (Fig. 3C ).
ADAMTS3 mutants are unable to cleave VEGFC
Absence of immunoreactive material in the conditioned medium of cells expressing the mutant ADAMTS3 did not completely rule out the possibility that an active ADAMTS3 fragment, which would encompass the metalloproteinase domain but not the epitopes recognized by the antibodies, could be secreted and active. Therefore, the functional consequences of the ADAMTS3 mutations on processing of pro-VEGFC were evaluated. HEK293 cells express endogenously CCBE1, which has been shown to increase the maturation of pro-VEGFC by ADAMTS3. Control HEK293 cells or HEK293 cells expressing the different forms of ADAMTS3 (WT, L168 or I291) were mixed at a 1:1 ratio with HEK293 cells expressing pro-VEGFC (Fig. 3D) . A complete conversion was observed in presence of WT-ADAMTS3, as illustrated by the almost total disappearance of the 31 kDa band, which is cleaved into a smaller product (less efficiently recognized by the antibody). In contrast, absence of cleavage was observed for the L168P and I291T-ADAMTS3 mutants.
ADAMTS3 mutants are sequestered within cells
To determine if the mutant ADAMTS3 enzymes accumulated in cells or were secreted but remained associated with the cell layer (Fig. 3B) , we performed immunofluorescence studies on non-permeabilized and permeabilized cells (Fig. 4) . Cells expressing WT-ADAMTS3 were faintly labeled, with or without permeabilization, with the N-terminal antibody (not shown) and the C-terminal antibody (Fig. 4) . Thus, taking into account all our experiments, processing and secretion of WT-ADAMTS3 was efficient, with normal cleavage of the C-terminal propeptidase domain and release into the conditioned medium. Similar amounts of ADAMTS3 were seen around non-permeabilized cells for the mutant proteins, but a significant accumulation of both L168P and I291T mutants was noted inside the cells after permeabilization, demonstrating impaired secretion (Fig. 4) .
Altogether, these data demonstrate altered maturation and absence of secretion of ADAMTS3 mutants, explaining the absence of processing of pro-VEGFC into active VEGFC (Fig. 3D ).
Discussion
The Hennekam syndrome, characterized by lymphangiectasia, lymphedema, and typical facial features and cognitive impairment, was described in 1989 (20) . In 2009, CCBE1 recessive mutations were shown to cause this syndrome (HKLLS1; OMIM 235510) (15) . CCBE1 is involved in processing of VEGFC, the main VEGFR3 ligand involved in lymphangiogenesis. CCBE1 deficiency in mice and zebrafish results in drastically impaired lymphatic vasculature (15, 17, 21) . A second gene, FAT4, encoding a protocadherin, has been reported to cause a Hennekam-like syndrome (HKLLS2; OMIM 616006) by homozygous or combined heterozygous mutations (4) . The function of FAT4 in lymphatic vasculature is unknown.
According to current in vitro and animal model data, CCBE1 requires ADAMTS3 for efficient processing and activation of VEGFC (Fig. 5A) . Pro-VEGFC binding to VEGFR3 is assisted by the N-terminal domain of CCBE1, but CCBE1 itself does not process VEGFC (14) ; rather, the cleavage is performed by ADAMTS3.
The CCBE1 N-terminal domain also binds to the extracellular matrix, thereby restricting the localization of VEGFC processing, whereas the C-terminal domain of CCBE1, containing two collagen repeats, is required for VEGFC activation (22) . Indeed, lack of the C-terminal domain mimics the Ccbe1 knockout (22) . The ADAMTS3-CCBE1 complex can also form independently of VEGFR3 and cleave VEGFC, but proper localization is required for adequate lymphangiogenesis (23) . ADAMTS3 seems a requisite for this. Indeed, we reported elsewhere that an ADAMTS3 change (c.1694 G > A; p.Arg595Gln), which does not change VEGFC processing but reduces ADAMTS3 interaction with CCBE1, renders ADAMTS3 unable to retain CCBE1 at the cell surface, resulting in disruption of VEGFR3 signaling (24) .
Here, we identified two compound heterozygous recessive mutations in ADAMTS3 in two siblings with primary lymphedema, lymphangiectasia and distinct facial features. The symptoms are reminiscent of those of Hennekam syndrome 1, caused by CCBE1 mutations (OMIM 235510), underscoring the likely cooperative function of the two proteins in the same cellular process. We propose to name this clinical entity caused by ADAMTS3 mutations Hennekam lymphangiectasia-lymphedema syndrome 3 (HKLLS3), given that HKLLS2 (OMIM 616006) is caused by FAT4 mutations (4). The two identified mutations (c.503 T > C; p.Leu168Pro and c.872 T > C; p.Ile291Thr) result in loss of function of ADAMTS3 and defective VEGFC activation (Fig. 5B) . Each of the mutations was present in one of the parents, who were unaffected. Thus, haploinsufficiency of ADAMTS3 is not pathogenic; 50% of enzyme is sufficient to cleave and activate enough VEGFC. This is in agreement with our previous observations that heterozygous Adamts3 þ/À mice were healthy and reproduced well (25) .
Our in vitro experiments demonstrated that the two mutants of ADAMTS3 displayed an abnormal electrophoretic profile (Fig. 3) . Similar to ADAMTS2 (18) , the activity of ADAMTS3 is largely regulated by several proteolytic processes (Supplementary Material, Fig. S1 ). Two main cleavages are required to confer full activity. First, the prodomain must be excised by proprotein convertases, such as furin, at a specific basic site (MRRRRH in ADAMTS3), between the prodomain and the peptidase domain. The second crucial cleavage occurs at the beginning of the C-terminal procollagen N-propeptidase (PNP) domain, at a site not yet precisely identified. This cleavage might be performed through an autocatalytic process. Persistence of the PNP domain in the homologous ADAMTS2 strongly reduced its activity and leads to formation of aggregates at the cell surface and in the extracellular matrix (Colige et al., unpublished) . Although the exact mechanism of inhibition is unknown, the PNP domain could reduce interactions with the substrates (18) .
The discovery of reduced mutant ADAMTS3 activity could reflect very low bio-availability of the enzyme. In our experiments, the maturation process of the WT-ADAMTS3 occurred as expected. In contrast, the two mutations have dramatic consequences on ADAMTS3 secretion and maturation. None of the mutants was detected in the conditioned medium (Fig. 3) , whereas strong intracellular accumulation was evident by immunofluorescence (Fig. 4) . The L168P mutant accumulates in the cell layer in its full-size, possibly because its cleavage by proprotein convertases is hampered. For the I291T mutant, products of abnormal sizes were also observed (Fig. 3B) , clearly illustrating maturation defects. Altogether, absence of secretion and abnormal processing explain why the mutants of ADAMTS3 were unable to cleave and activate pro-VEGFC in the extracellular compartment.
Amelioration of the lymphedema with fever in our patients is an intriguing clinical observation. It raises the hypothesis that the mutations are temperature sensitive and that elevated temperatures may result in improved protein secretion. To address this question, we cultured WT and mutants ADAMTS3 Fig. S2 ). However, no secretion of the mutants was seen in any condition, and even the secretion and activation of the WT ADAMTS3 was impaired at 41 C. Thus, this clinical observation remains unexplained.
The bi-allelic loss of function of ADAMTS3 reported here is not lethal in human beings. In contrast, the Adamts3 À/À mice died around E15.0 with severe edema due to complete lack of lymphatic vessels (25) . Several hypotheses can be made to explain these differential effects. Species-specific compensation by other enzymes during embryonic development could occur, although ADAMTS2 and ADAMTS14 (the two closest homologs of ADAMTS3) are unable to cleave pro-VEGFC in vitro (Colige et al., unpublished). Activation and secretion of the mutant ADAMTS3 might also be less affected in vivo during embryogenesis than in HEK293 cells, providing sufficient residual activity for embryonic survival, but insufficient activity for normal development and/or homeostasis of the lymphatic network. In addition to endothelial cells, ADAMTS3 is significantly expressed in other tissues, such as in cartilage where it is considered to be the enzyme responsible for cleavage of the aminopropeptide of type II procollagen. Since our patients do not have developmental delay or major skeletal defects, it probably indicates that lack of ADAMTS3 secretion is compensated, at least partially, by another collagen aminopeptidase, likely ADAMTS2 (25) . However, involvement of ADAMTS3 in type II procollagen maturation could explain the characteristic facial features of the subjects. It also suggests that periodic evaluation of cartilage and joint integrity of the patients may be indicated. ADAMTS3 is also strongly expressed in the brain, but no obvious neurological disorder was identified in the patients. Finally, the Adamts3 -/-mice present with reduced liver development (25) .
No obvious signs of hepatic dysfunction were evidenced in our patients, albeit no extensive liver evaluation was performed.
In conclusion, our discovery of ADAMTS3 mutations in human subjects with lymphangiectasia, lymphedema and distinct facial features (Hennekam lymphangiectasia-lymphedema syndrome 3) reveals another key component in the development of primary lymphedema. Therefore, individuals with phenotypic signs reminiscent of the Hennekam syndrome need to be screened not only for CCBE1 and FAT4 mutations, but also for alterations in ADAMTS3. These data give unequivocal evidence for the important physiological role that ADAMTS3 plays in VEGFC activation in man. 
Materials and Methods
Patients and sequencing
DNA samples and phenotypic data from family LE-69 (Fig. 1A) were collected (G.T. and J.P.). Informed consent was obtained from the patients prior to their participation in the study, as approved by the Ethical Committee of the Medical Faculty at University of Louvain (Brussels, Belgium) and the Committee for the Protection of Human Subjects of Vanderbilt University (Nashville, TN, USA). DNA was extracted using the Wizard Genomic kit (Promega) and concentration measured on a Nanodrop 8000 (Thermo Scientific). Exome sequencing of the index case (LE-69.10) was performed on a SOLiD 5500xl with a Wildfire module (Life Technologies), after exon capture with SureSelect v5 kit (Agilent). The reads were aligned with Lifescope (Life Technologies) and bam files were imported into Highlander for analysis (http://sites.uclouvain.be/highlander/), a software developed in our laboratory (Helaers et al, under revision). Variants were called with the Genome Analysis Toolkit (GATK, Broad Institute) and annotated with a number of software programs, including dbNSFP v2 (26) .
Filtering in Highlander was performed using following criteria: variants within a list of $600 candidate genes; not detected in >3 distinct pathologies including lymphedema; read depth of at least 10 at this position; absent or present at <0, 15% (corresponding to the estimated prevalence of primary lymphedema in the population) in the Exome Aggregation Consortium database (ExAC, http://exac.broadinstitute.org); predicted damaging by at least four prediction software programs; and visually evaluated in the Integrative Genomics Viewer (IGV, http://software. broadinstitute.org/software/igv/). The underlying hypothesis was recessive inheritance, and thus only genes with a homozygous mutation or two independent mutations were kept.
We used PCR and Sanger sequencing with genomic primers 
Expression vectors
The pcDNA4/TO vector containing the human ADAMTS3 coding sequence (26) was used for site-directed mutagenesis. Oligonucleotides were designed using QuikChange Primer Design (Agilent). (Fig. 1B) . This KpnI cassette was subsequently replaced in the wild-type (WT) and mutant expression vectors. For VEGFC expression, the full-length human coding sequence (22) was inserted between the BamHI and XbaI sites of pcDNA4/ TO (TetOn System; Invitrogen). Plasmids were purified with the Plasmid Maxi kit (Qiagen) and sequence-verified.
Stable cell lines
Human embryonic kidney HEK293 cells expressing a tetracyclin-sensitive repressor (27) were transfected with wildtype or mutant ADAMTS3 or VEGFC expression vectors, using GeneJuice Transfection Reagent (Novagen). After selection (Zeocin, 300 mg/ml; Thermo Fisher Scientific), subcloning was performed to identify clones producing the recombinant proteins only when induced with 1 mg/ml doxycycline (SigmaAldrich). Selected clones were subsequently cultured in DMEM supplemented with Zeocin (300 mg/ml), blasticidin (4 mg/ml) and 10% fetal bovine serum.
ADAMTS3 profiling
Transfected HEK293 cells conditionally expressing wild-type or mutant ADAMTS3 (HA-tagged or not) were cultured until confluent. The culture medium was then replaced by fresh medium containing doxycycline (1 mg/ml) to induce ADAMTS3 expression. After 48 h, the conditioned media were collected and the cell layers were scraped in Laemmli denaturation buffer (with 100 mM DTT). Samples were separated by electrophoresis (7.5 or 12.5% SDS-PAGE) and transferred to PVDF membrane (NEN Life Sciences Products). Membranes were blocked (60 min, 3% BSA in PBS-Tween) and incubated with the anti-ADAMTS3 antibody (sc-21486, Santa Cruz, recognizing the C-terminal part, or AF5465, R&D Systems, raised against the N-terminal part) or with the anti-HA antibody (11867423001, Roche) for 18 h at 4 C.
The secondary peroxidase-conjugated antibodies (1 h at RT; 1/ 2000) were from Dako. Peroxidase activity was revealed with an enhanced chemiluminescence assay (ECL TM Prime Western Blotting System, Sigma Aldrich) in an ImageQuant TM LAS 4000
(GE Healthcare).
VEGFC processing
HEK293 cells transfected to conditionally express ADAMTS3 or VEGFC were co-cultured at a 1:1 ratio. At confluence, doxycycline was added for 48 h. The conditioned media were collected and the cell layers were scraped in Laemmli denaturation buffer (with 100 mM DTT). Samples were resolved on 12.5% SDS-PAGE) and transferred to PVDF. Membranes were blocked (60 min in 3% BSA in PBS-Tween) and incubated 18 h at 4 C with the anti-VEGFC antibody (AF2179, R&D Systems), followed by an antisheep peroxidase-conjugated secondary antibody (1/2000, Dako) . Peroxidase activity was revealed as described above.
ADAMTS3 cytochemistry
HEK293 cells conditionally expressing wild-type or mutant ADAMTS3 were cultured until 50% confluent, then treated with doxycycline for 48 h. After fixation (4% formaldehyde in PBS for 10 min), cells were either left untreated, or permeabilized (3 min in PBS containing 0.1% Triton X-100). ADAMTS3 staining was performed using two different antibodies (sc-21486 from Santa Cruz and AF5465 from R&D Systems, at a 1/50 dilution) for 2 h at 37 C, followed by Alexa Fluor-546 donkey anti-goat IgG (A11056, Life Technologies) or Fluor-488 rabbit anti-sheep IgG (ab150181, Abcam) for 1 h. Nuclei were counter-stained with DAPI (1/1000, Life Technologies, D1306) in PBS. After mounting in Dako fluorescent mounting medium (s3023, Dako), cells were observed with an Eclipse TiS microscope (Nikon). Genbank accession number for ADAMTS3 mRNA: NM_014243. The variants were submitted to LOVD (adamts3.lovd.nl).
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